Alivus Life Sciences Limited
Fundamental Score
Alivus Life Sciences Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ALIVUS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (18.69%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.92%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (29.62%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 20.98 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (36.41%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (16.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (167.33x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹1442.00 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
1 factors identified
Weak Earnings Growth (-52.37% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Financial Statements
Comprehensive financial data for Alivus Life Sciences Limited
About ALIVUS
Business Overview
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Company Details
Key Leadership
Corporate Events
ALIVUS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Alivus Life Sciences Limited (ALIVUS)?
As of 30 Jan 2026, 01:36 pm IST, Alivus Life Sciences Limited (ALIVUS) is currently trading at ₹961.05. The stock has a market capitalization of ₹11.13K (Cr).
Is ALIVUS share price Overvalued or Undervalued?
ALIVUS is currently trading at a P/E ratio of 20.98x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Alivus Life Sciences Limited share price?
Key factors influencing ALIVUS's price include its quarterly earnings growth (Sales Growth: 16.00%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alivus Life Sciences Limited a good stock for long-term investment?
Alivus Life Sciences Limited shows a 5-year Profit Growth of 8.92% and an ROE of 18.69%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing.
How does Alivus Life Sciences Limited compare with its industry peers?
Alivus Life Sciences Limited competes with major peers in the Pharmaceuticals. Investors should compare ALIVUS's P/E of 20.98x and ROE of 18.69% against the industry averages to determine its competitive standing.
What is the P/E ratio of ALIVUS and what does it mean?
ALIVUS has a P/E ratio of 20.98x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.
How is ALIVUS performing according to Bull Run's analysis?
ALIVUS has a Bull Run fundamental score of 68.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ALIVUS belong to?
ALIVUS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alivus Life Sciences Limited.
What is Return on Equity (ROE) and why is it important for ALIVUS?
ALIVUS has an ROE of 18.69%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Alivus Life Sciences Limited generates profits from shareholders' equity.
How is ALIVUS's debt-to-equity ratio and what does it indicate?
ALIVUS has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ALIVUS's dividend yield and is it a good dividend stock?
ALIVUS offers a dividend yield of 0.55%, which means you receive ₹0.55 annual dividend for every ₹100 invested.
How has ALIVUS grown over the past 5 years?
ALIVUS has achieved 5-year growth rates of: Sales Growth 9.20%, Profit Growth 8.92%, and EPS Growth -52.37%.
What is the promoter holding in ALIVUS and why does it matter?
Promoters hold 74.91% of ALIVUS shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ALIVUS's market capitalization category?
ALIVUS has a market capitalization of ₹11126 crores, placing it in the Mid-cap category.
How volatile is ALIVUS stock?
ALIVUS has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ALIVUS?
ALIVUS has a 52-week high of ₹N/A and low of ₹N/A.
What is ALIVUS's operating profit margin trend?
ALIVUS has a 5-year average Operating Profit Margin (OPM) of 29.62%, indicating the company's operational efficiency.
How is ALIVUS's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 16.00% and YoY Profit Growth of 36.41%.
What is the institutional holding pattern in ALIVUS?
ALIVUS has FII holding of 6.84% and DII holding of 5.47%. Significant institutional holding often suggests professional confidence in the stock.